Kaia Health Reduces Back Pain by 46% in Rise-uP Randomized Controlled Trial Results

Digital therapeutic delivers gold-standard treatment for nonspecific back pain, improves function and quality of life outcomes. Kaia Health users experienced pain reduction of 1.85 points after only 3 months Cost-effectiveness analysis shows a reduction in healthcare costs of up to 80% versus traditional care Federal Joint Committee (G-BA),3 has recommended applying the approach of Rise-uP … [Read more…]

Navitus Health Solutions Selected by Health Transformation Alliance as Pharmacy Benefit Manager Partner

MADISON, Wis.–(BUSINESS WIRE)–Navitus Health Solutions, an industry-disrupting pharmacy benefit manager (PBM) that’s committed to bringing humanity to pharmacy benefits management through greater transparency and affordability, announced today that it has been selected as a partner by the Health Transformation Alliance (HTA) to provide best-in-class PBM services for its members. Through this partnership, Navitus will offer … [Read more…]

LG Chem Enters Final Stage of Clinical Development for New Gout Drug

SEOUL, South Korea & CAMBRIDGE, Mass.–(BUSINESS WIRE)–#Gout–LG Chem recently announced that the Company has submitted an IND application to the US FDA for its first independent global Phase 3 clinical trial of its new gout drug ‘Tigulixostat’ (clinical program name: EURELIA_1 Study). LG Chem’s strategy is to expand its life sciences business and to reach … [Read more…]

Model N and Pfizer Innovate Drug Price Transparency Reporting

NEW ‘Transparency Talks’ With Pfizer and Global Pricing Innovations (GPI) Help Pharmaceutical Companies Stay Compliant With Drug Pricing SAN MATEO, Calif.–(BUSINESS WIRE)–#LifeSciences—Model N, Inc. (NYSE: MODN), the leader in revenue optimization and compliance, today announced the launch of Transparency Talks, a new, three-part education series for pharmaceutical companies that tackles the topic of price transparency … [Read more…]

Know Labs Files S-1 for New Share Offering, Seeks Uplist to NYSE American Exchange

SEATTLE–(BUSINESS WIRE)–Know Labs, Inc. (OTCQB: KNWN) an emerging developer of non-invasive medical diagnostic technology, today announced it has filed a Form S-1 registration statement for a proposed new offering of 3 million shares of its common stock with an anticipated offering price of $2.00 per share. Concurrent with, and as a condition to, the offering, … [Read more…]

Kelly Roland Promoted to President of Texas Original

AUSTIN, Texas–(BUSINESS WIRE)–Texas Original, Texas’ leading medical cannabis provider, announced that Kelly Roland has been promoted to president. Roland served as Texas Original’s senior vice president of sales and chief revenue officer for three years. During that time, she oversaw and drove the company’s rise to its commanding leadership position in Texas’ growing cannabis market. … [Read more…]

Amylyx Pharmaceuticals Announces FDA Advisory Committee Will Reconvene to Review New Drug Application for AMX0035 for the Treatment of ALS on September 7, 2022

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) will reconvene to review the New Drug Application (NDA) for AMX0035 (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]) for the treatment of amyotrophic lateral sclerosis (ALS). The second … [Read more…]

Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Jaén and Granada

Research Evaluates Effects of Against the Tumor Microenvironment MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a Joint Research Collaboration Agreement has been established with the Universities of Jaén and Granada, Spain. Since late … [Read more…]

Eureka Therapeutics Announces Publication of Crystal Structure of TCR Mimic Redirected T Cells Targeting Alpha-Fetoprotein (AFP) for Liver Cancer

EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the publication of a study in Nature’s Scientific Reports entitled “Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma”. The study was led by Dr. Cheng Liu, President and Chief … [Read more…]